COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02518529
Recruitment Status : Completed
First Posted : August 10, 2015
Last Update Posted : August 10, 2015
ChapelPharma Ltd
Information provided by (Responsible Party):
Cancer Advances Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 2002
Actual Study Completion Date : December 2002